Cancer Drug Launch Prices Skyrocket Beyond Inflation
Medicare Part D anticancer drugs' launch prices have surged since 2012, even outpacing inflation rates, despite the Inflation Reduction Act.
Browsing Tag
drug pricing
Trump Wins Presidency: A New Era for Federal Health Agencies Begins
Donald Trump has won the presidency, marking a new era for federal health agencies. He promised to shake up public…
Poll: Inflation Reduction Act raises voter awareness on drug pricing
TL/DR -
A new poll from health policy research group KFF found that while President Biden's messaging for the…
Etanercept Biosimilar Launch Saves Aussie Govt $6M: Pricing Policy Update
TL/DR -
The United States has approved two biosimilars for etanercept (Enbrel) but patent litigation has delayed their market launch until 2029. Sales of Enbrel reached $4 billion in 2022, and the drug is being targeted for Medicare price negotiation under the Inflation Reduction Act. Meanwhile, Australia has been using the first etanercept…